Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;24(9):1189-1195.
doi: 10.1007/s11886-022-01735-z. Epub 2022 Jul 16.

Update on the Genetics of Primary Aldosteronism and Aldosterone-Producing Adenomas

Affiliations
Review

Update on the Genetics of Primary Aldosteronism and Aldosterone-Producing Adenomas

Georgia Pitsava et al. Curr Cardiol Rep. 2022 Sep.

Abstract

Purpose of the review: Primary aldosteronism (PA) is the leading cause of secondary hypertension, accounting for over 10% of patients with high blood pressure. It is characterized by autonomous production of aldosterone from the adrenal glands leading to low-renin levels. The two most common forms arise from bilateral adrenocortical hyperplasia (BAH) and aldosterone-producing adenoma (APA). We discuss recent discoveries in the genetics of PA.

Recent findings: Most APAs harbor variants in the KCNJ5, CACNA1D, ATP1A1, ATP2B3, and CTNNB1 genes. With the exception of β-catenin (CTNNB1), all other causative genes encode ion channels; pathogenic variants found in PA lead to altered ion transportation, cell membrane depolarization, and consequently aldosterone overproduction. Some of these genes are found mutated in the germline state (CYP11B2, CLCN2, KCNJ5, CACNA1H, and CACNA1D), leading then to familial hyperaldosteronism, and often BAH rather than single APAs. Several genetic defects in the germline or somatic state have been identified in PA. Understanding how these molecular abnormalities lead to excess aldosterone contributes significantly to the elucidation of the pathophysiology of low-renin hypertension. It may also lead to new and more effective therapies for this disease acting at the molecular level.

Keywords: Aldosterone-producing adenoma; Hypertension; Primary aldosteronism; Resistant hypertension.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest declarations

Dr. Hannah-Shmouni is a member of the Endocrine Hypertension Subcommittee of the Canadian Hypertension Guidelines (Hypertension Canada) and has no relevant disclosures to report.

Dr. Stratakis holds patents on the PRKAR1A, PDE11A, and GPR101 genes and/or their function and has received research funding from Pfizer Inc. on the genetics and treatment of abnormalities of growth hormone secretion. Dr. Stratakis is currently employed by ELPEN Pharmaceuticals and has received consulting fees from Sync, Lundbeck, and Sandoz. Dr. Stratakis also reports grant support from the NIH.

Dr. Faucz holds a patent on the GPR101 gene and its function.

Dr. Pitsava has no conflicts of interest.

References

    1. Lim SS, et al., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012. 380(9859): p. 2224–60. 10.1016/S0140-6736(12)61766-8 - DOI - PMC - PubMed
    1. Brown JM, et al., The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med, 2020. 173(1): p. 10–20. 10.7326/M20-0065 - DOI - PMC - PubMed
    1. Monticone S, et al., Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol, 2017. 69(14): p. 1811–1820. 10.1016/j.jacc.2017.01.052 - DOI - PubMed
    1. El-Asmar N, Rajpal A, and Arafah BM, Primary Hyperaldosteronism: Approach to Diagnosis and Management. Med Clin North Am, 2021. 105(6): p. 1065–1080. 10.1016/j.mcna.2021.06.007 - DOI - PubMed
    1. Rossi GP, et al., A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol, 2006. 48(11): p. 2293–300. 10.1016/j.jacc.2006.07.059 - DOI - PubMed

MeSH terms

Substances